secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0000950170-23-016879
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q1 YUTIQ revenue up 60% to $7.4M; DAVIO 2 top-line data on track for Q4 2023
--------------------------------------------------------------------------------

- YUTIQ net product revenue $7.4M, up 60% YoY; customer demand 930 units (+43% YoY).
- Net loss $21.2M ($0.56/share); cash and investments $122.5M, down from $144.6M at Dec 31, 2022.
- Phase 2 DAVIO 2 trial for wet AMD fully enrolled (160 patients, oversubscribed); topline data expected Q4 2023.
- Phase 2 PAVIA trial for NPDR enrollment accelerated to 60 patients; data expected H1 2024; Phase 3 initiation advanced.
- Leased 40,000 sq ft manufacturing facility in Northbridge, MA; awarded $1.9M state/local grants; cash runway into H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023016879/0000950170-23-016879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023016879/eypt-20230503.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-016879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer